Treatment-Resistant OCD

The short version

●OCD is considered treatment-resistant when obsessions and compulsions persist despite adequate trials of SSRIs (often at high doses) and exposure and response prevention (ERP).
●ERP — a specific form of CBT — is the single most effective treatment and is essential before declaring resistance; many "resistant" cases simply haven't had proper ERP.
●Standard escalation includes maximizing SSRI dose, switching SSRIs, adding clomipramine, and augmenting with an antipsychotic.
●A randomized controlled crossover trial found a single ketamine infusion produced rapid reductions in OCD symptoms in some unmedicated patients¹ — a notable but early signal.
●The OCD evidence for ketamine is far thinner and less durable than for depression; benefits appear smaller and shorter-lived, so it is investigational, not standard.² ³
●Tovani's focus is depression, anxiety, PTSD, and chronic pain; ketamine for OCD specifically is not an established indication and is best pursued in specialist or research settings.

Clinical definition

Obsessive-compulsive disorder is defined by obsessions (intrusive, unwanted thoughts, urges, or images) and/or compulsions (repetitive behaviors or mental acts performed to reduce distress), which are time-consuming or cause significant impairment. OCD is considered treatment-resistant (or treatment-refractory) when it fails to respond adequately to first-line treatment — typically defined as inadequate response to two or more adequate SSRI trials (frequently requiring higher doses and longer durations than in depression) plus an adequate course of exposure and response prevention. Because OCD often needs higher SSRI doses and 10–12 weeks to respond, true resistance should be distinguished from undertreatment.

How it differs from related conditions

vs. OCD

Treatment-resistant OCD is the same disorder after first-line treatments have genuinely failed — the distinction is the treatment history, not different symptoms.

vs. Body dysmorphic disorder

A related obsessive-compulsive-spectrum disorder focused on perceived appearance flaws; treated similarly but a distinct diagnosis.

vs. Generalized anxiety disorder

GAD worry is about real-life concerns and lacks the ritualized compulsions of OCD; the two are sometimes confused but respond to different therapies.

First-line treatments

Exposure & response prevention (ERP)

The most effective treatment for OCD and the backbone of care; proper ERP is required before calling OCD resistant.

High-dose SSRIs

OCD typically needs higher SSRI doses and longer trials than depression; this must be optimized before declaring resistance.

Clomipramine

A tricyclic with strong OCD evidence, used when SSRIs are insufficient.

Antipsychotic augmentation

Adding a low-dose antipsychotic to an SSRI helps a subset of resistant cases.

When standard treatments fail

For OCD resistant to optimized ERP and pharmacotherapy, specialist options include intensive residential ERP programs, clomipramine, antipsychotic augmentation, and — in severe, highly refractory cases — neurosurgical approaches such as deep brain stimulation. Glutamate-modulating agents, including ketamine, are under active investigation but remain experimental for OCD.

Where ketamine fits

The rationale for ketamine in OCD is glutamatergic: OCD involves cortico-striatal glutamate dysregulation, and a randomized controlled crossover trial reported that a single ketamine infusion rapidly reduced OCD symptoms in some unmedicated patients — the first such controlled signal.¹ Small studies have also paired intranasal ketamine with CBT.² However, the evidence base is far smaller and the effects appear less robust and less durable than in depression,³ so ketamine for OCD is genuinely investigational rather than an established treatment. It is most appropriately pursued through specialist OCD or research programs, ideally still anchored by ERP. Where a patient has co-occurring treatment-resistant depression, ketamine may be considered for the depression.

Where this fits with Tovani

Tovani's established indications are depression, anxiety, PTSD, and certain chronic pain conditions — not OCD as a primary target, where the evidence is still early. We'd encourage anyone with treatment-resistant OCD to ensure they've had proper exposure and response prevention, which is the most effective treatment and is often the missing piece. If treatment-resistant depression co-occurs, that depression may be a candidate for ketamine.

Check eligibility Find treatment options The science behind ketamine

Frequently asked

Does ketamine treat OCD?

It's investigational. A controlled trial found a single infusion rapidly reduced OCD symptoms in some unmedicated patients, which is promising — but the evidence is much thinner and less durable than for depression. It's not an established OCD treatment, and exposure and response prevention (ERP) remains the most effective approach.

My OCD hasn't responded to medication — is it treatment-resistant?

Maybe — but first make sure you've had proper ERP and adequate, high-dose SSRI trials (OCD needs higher doses and longer than depression). Many "resistant" cases are actually undertreated. True resistance is failure despite optimized ERP plus two adequate SSRI trials.

What's the most effective OCD treatment?

Exposure and response prevention (ERP), a specific form of CBT, is the single most effective treatment — often more so than medication. High-dose SSRIs, clomipramine, and antipsychotic augmentation are the medication options. It's the missing ingredient in many treatment-resistant cases.

Does Tovani offer ketamine for OCD?

Our established indications are depression, anxiety, PTSD, and certain chronic pain — not OCD, where ketamine evidence is still early. If you also have treatment-resistant depression, that depression could be a candidate. For OCD itself, specialist ERP and a research setting are the better routes.

References

Rodriguez CI et al. 2013, Neuropsychopharmacology — Randomized controlled crossover trial: a single ketamine infusion rapidly reduced OCD symptoms in unmedicated patients. (PMID 23783065)
Adams TG et al. 2017, Journal of Clinical Psychopharmacology — Pilot work combining intranasal ketamine with cognitive-behavioral therapy for treatment-refractory OCD. (PMID 28121735)
Hirschtritt ME et al. 2017, JAMA — Review of OCD diagnosis and treatment, framing ERP and SSRIs as the evidence-based foundation. (PMID 28384832)

Last reviewed by Dr. Ben Soffer, DO on June 2, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.